Replies to post #39089 on Ocata Therapeutics Inc fka OCAT

[interstate]

Rocky,

"Yes, we used the single-cell biopsy method (but we discarded the embryo afterwards). However, we have several hESC (human embryonic stem cell) lines where the embryos were not destroyed -- we plan to switch to those hESC lines in future (phase 3/4) clinical trials."

Is there any way the FDA will let them do this without restarting the whole trial. I thought they had to stick with MA09 though out the trials since all the animal studies and pre-clinical trials used MA09. There is no way the FDA will let them use the other lines without simlar test. IMO

[Titan V]

Rocky, thanks for the clarification and also for the link.